Real-world early- to midterm outcomes of aortic valve replacement using novel tissue technology bioprosthesis at a high-volume center

Objective: The INSPIRIS-RESILIA aortic valve (Edwards Lifesciences) uses a novel tissue-fixation technology to enhance the bioprosthesis's longevity. We sought to report midterm INSPIRIS-RESILIA aortic bioprosthesis performance in a large contemporary cohort at a single institution. Methods: Between January 2013 and July 2024, 9168 patients underwent surgical aortic valve replacement at our center, of which 3758 patients received an INSPIRIS-RESILIA bioprosthesis. Propensity-match analysis between INSPIRIS-RESILIA and PERIMOUNT valves (n = 2480 in each group) was executed. Median follow-up in the INSPIRIS-RESILIA was 2.5 years, and 25% of patients were followed for more than 4.8 years. Results: > .2) between the 2 bioprostheses in the propensity-matched analysis. Conclusions: This single-center study of the real-world experience with the INSPIRIS-RESILIA bioprosthesis has demonstrated favorable hemodynamic performance and a low rate of reintervention at early- to midterm follow-up.